{
    "clinical_study": {
        "@rank": "28590", 
        "acronym": "ECRL1", 
        "arm_group": [
            {
                "arm_group_label": "Pangramin Plus D. pteronyssinus", 
                "arm_group_type": "Active Comparator", 
                "description": "Pangramin Plus D. pteronyssinus 100% for subcutaneous injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of an extract of Dermatophagoides pteronyssinus versus placebo in\n      the treatment of local allergic rhinitis. The primary efficacy endpoint is the reduction in\n      symptom scores and medication use in the active group compared to placebo.\n\n      The influence of treatment in \"in vitro\" and \"in vivo\" objective parameters was also\n      assessed."
        }, 
        "brief_title": "Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis", 
        "condition": "Local Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Prior to study specific examinations the patient  has to give his/her written\n             informed consent.\n\n          -  Local allergic rhinitis induced by Dermatophagoides pteronyssinus (DP).\n\n          -  Age: 18-55.\n\n          -  Negative skin prick-test to DP\n\n          -  Positive nasal allergen provocation test to DP (NAPT-DP) and/or nasal specific IgE\n             (sIgE) to DP>0.35 kU/L\n\n          -  If applicable negative urine pregnancy test and willingness to use effective form of\n             contraception for the duration of involvement in the study.\n\n        Exclusion Criteria:\n\n          -  Severe immunopathological or immunodeficiencies diseases.\n\n          -  Treatment with beta-blockers, even when administered topically\n\n          -  Severe psychological disorders\n\n          -  Severe Atopic Dermatitis\n\n          -  FEV1 <70% predicted after appropriate pharmacological treatment\n\n          -  History of hypersensitivity or intolerance to excipients and / or trial medication or\n             other medication to be used for protocol\n\n          -  Inability to adequately perform diagnostic tests or treatment\n\n          -  Awareness of other inhaled allergens (perennial or seasonal) clinically relevant to\n             the subject and that may interfere with the response evaluation\n\n          -  Treatment with immunotherapy in the 5 years prior to his inclusion in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123316", 
            "org_study_id": "ECRL12008-003680-39", 
            "secondary_id": "2008-003680-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pangramin Plus D. pteronyssinus", 
                "description": "Subcutaneous immunotherapy with Dermatophagoides pteronyssinus", 
                "intervention_name": "Pangramin Plus D. pteronyssinus", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo for subcutaneous injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "local allergic rhinitis", 
            "subcutaneous immunotherapy", 
            "house dust mite allergy", 
            "Dermatophagoides pteronyssinus allergy"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Malaga", 
                    "country": "Spain", 
                    "zip": "29009"
                }, 
                "name": "Hospital Carlos Haya"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of the Effectiveness of a Dermatophagoides Pteronyssinus Extract, Rated in Units of Mass and Administered Subcutaneously for the Treatment of Local Allergic Rhinitis. Randomized, Double-blind, Placebo-controlled Study.", 
        "overall_official": {
            "affiliation": "Allergy Unit, Regional University Hospital of Malaga, Spain", 
            "last_name": "Miguel Blanca, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients were provided a diary to score the severity of their symptoms and the use of rescue medication during 4 consecutive weeks.\nNasal symptoms of rhinorrhea, nasal congestion, sneezing, nasal itching, and ocular symptoms were recorded using a 4-point categorical scale from 0 to 3 (0: no symptoms, 1:mild, 2:moderate; 3:severe).\nThe use of rescue medication was recorded in the patient diary according to the following score:\nOral antihistamines (1 tablet = 1 point); intranasal corticosteroids (400mcg/day of beclometasone or equivalent = 1.4 points); and ocular antihistamines (1 dose = 1 point).", 
            "measure": "Change from Baseline Symptoms-Medication score at 1,3,6,12,18, and 24 months", 
            "safety_issue": "No", 
            "time_frame": "Baseline, month 1,3,6,12,18, and 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123316"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Plaza del Hospital Civil", 
            "investigator_full_name": "Miguel Blanca Gomez", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline response skin prick-test at 1,3,6,12,18, and 24 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline, month 1,3,6,12,18, and 24"
            }, 
            {
                "measure": "Change from Baseline response to intradermal test at 1,3,6,12 and 24 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline, month 1,3,6,12,18, and 24"
            }, 
            {
                "measure": "Change from Baseline flow cytometry study at 1,3,6,12,18, and 24 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline, month 1,3,6,12,18, and 24"
            }, 
            {
                "measure": "Change from Baseline determination of tryptase, eosinophilic cationic protein, IgG, IgG4 and specific D. pteronyssinus-IgE by Immunoassay at 1,3,6,12,18, and 24 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline, month 1,3,6,12,18 and 24"
            }, 
            {
                "measure": "Change from Baseline response to nasal allergen provocation test with Dermatophagoides pteronyssinus at 1,3,6,12,18 and 24 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline, month 1,3,6,12,18 and 24"
            }, 
            {
                "measure": "Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Plaza del Hospital Civil", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Miguel Blanca Gomez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}